Document is current
Any future updates will be listed below
-
Authors
Florentino, Pilar T. V. https://orcid.org/0000-0001-8077-8100
Alves, Flávia J. O. https://orcid.org/0000-0003-1613-2270
Cerqueira-Silva, Thiago https://orcid.org/0000-0003-4534-2509
Oliveira, Vinicius de Araújo https://orcid.org/0000-0001-7858-9650
Júnior, Juracy B. S.
Jantsch, Adelson G.
Penna, Gerson O. https://orcid.org/0000-0001-8967-536X
Boaventura, Viviane
Werneck, Guilherme L. https://orcid.org/0000-0003-1169-1436
Rodrigues, Laura C.
Pearce, Neil
Barral-Netto, Manoel https://orcid.org/0000-0002-5823-7903
Barreto, Mauricio L.
Paixão, Enny S. https://orcid.org/0000-0002-4797-908X
- License Information
-
More Information
Article History
Received: 28 April 2022
Accepted: 3 August 2022
First Online: 13 August 2022
Competing interests
: M.B.-N. reports grants from the Fazer o bem faz bem program from JBS. S.A. V.dA.O., V.B., M.L.B., and M.B.-N. are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for public health use. The remaining authors declare no competing interests.
